| Expression pattern: |
UP |
| Associated gene: |
G6PC2, IRS-1 |
| Associated microRNA: |
hsa-miR-338-3p |
| Biological function: |
Aggravates abnormal glucose metabolism and insulin resistance; inhibits glucose uptake; represses IRS-1 activation |
| Molecular mechanism: |
Acts as a miRNA sponge for hsa-miR-338-3p to regulate G6PC2 expression and insulin signaling (IRS-1 activation). |
| Biological pathway or process: |
ceRNA regulation (promotes); glucose metabolism (other); insulin resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Sanger Sequencing; FISH / smFISH; Luciferase Reporter Assay; Transfection; Western Blot; Clinical Sample Validation; In Vivo Animal Model; H&E Staining; Bioinformatics Analysis |
| Clinical significance: |
hsa_circ_0046060 was identified as a potential candidate for diagnosing and treating GDM. |
| Description: |
In GDM, exosomal hsa_circ_0046060 is upregulated and aggravates abnormal glucose metabolism/insulin resistance. It functions mainly via a ceRNA mechanism by sponging hsa-miR-338-3p, leading to increased G6PC2 and reduced IRS-1 activation; silencing hsa_circ_0046060 in exosomes reverses these effects in L-02 cells and a diet-induced GDM mouse model. |
| Confidence score: |
0.7759 |